RecruitingNot ApplicableNCT07178639

Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery


Sponsor

Nemocnice Kolín

Enrollment

150 participants

Start Date

Aug 1, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial is to learn which of the drugs bromfenac 0.09%, nepafenac 0.3% and diclofenac 0.1% has better efficacy in treatment and prevention of cystoid macular oedema after cataract surgery. The main questions it aims to answer are: Which of the drugs has better efficacy in macular oedema prevention? What medical problems do participants have when taking different drugs? Researchers will compare drugs to each other. Participants will: Take on of the drugs (randomized) as their treatment in preoperative and postoperative period. Visit the clinic after the surgery on the first day, first week, in three weeks and in six weeks. Undergo retina examination with OCT (optical coherence tomography), best vision, and fill in forms considering their quality of life.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Bromfenac 0.09 % Ophthalmic Solution, a drug called Nepafenac 0.3% Oph Susp, and others for people with cataract surgery, macular oedema, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGBromfenac 0.09 % Ophthalmic Solution

Comparison of bromfenac ophthalmic solution 0.09% twice per day vs. nepafenac ophthalmic suspension 0.3% once per day vs. diclofenac ophthalmic suspension 0.1% four times per day for prevention of cystoid macular oedema associated with cataract surgery.

DRUGNepafenac 0.3% Oph Susp

Comparison of bromfenac ophthalmic solution 0.09% twice per day vs. nepafenac ophthalmic suspension 0.3% once per day vs. diclofenac ophthalmic suspension 0.1% four times per day for prevention of cystoid macular oedema associated with cataract surgery.

DRUGdiclofenac 0.1% ophthalmic susp.

Comparison of bromfenac ophthalmic solution 0.09% twice per day vs. nepafenac ophthalmic suspension 0.3% once per day vs. diclofenac ophthalmic suspension 0.1% four times per day for prevention of cystoid macular oedema associated with cataract surgery.


Locations(1)

Oblastní nemocnice Kolín a.s.

Kolín, Czechia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07178639


Related Trials